Aptevo Therapeutics Inc. (APVO): auditor change — Aptevo Therapeutics appoints Baker Tilly as new auditor after Moss Adams merger

Aptevo Therapeutics Inc.

Moss Adams merged with Baker Tilly effective June 3, 2025; Moss Adams resigned and Baker Tilly appointed for FY2025.
No disagreements or reportable events with Moss Adams during 2024/2023 and subsequent interim period.
Prior audit reports from Moss Adams included a going concern uncertainty explanatory paragraph.

item 4.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Auditor Changes SEC 8-K Item 4.01/4.02 confidence 0.9

Aptevo Therapeutics Inc. engaged Baker Tilly US, LLP as its auditor.

Action: engagement
Auditor: Baker Tilly US, LLP

Exact text from the filing

the Audit Committee of the Company’s Board of Directors approved the appointment of Baker Tilly, as the successor to Moss Adams, as the Company’s independent registered public accounting firm for the year ending December 31, 2025

View on SEC.gov

Auditor Changes SEC 8-K Item 4.01/4.02 confidence 0.9

Moss Adams LLP resigned as auditor of Aptevo Therapeutics Inc..

Action: resignation
Auditor: Moss Adams LLP
Successor: Baker Tilly US, LLP

Exact text from the filing

On June 23, 2025, Aptevo Therapeutics Inc., (the "Company") was notified that Moss Adams LLP ("Moss Adams"), the Company's independent registered public accounting firm, merged with Baker Tilly US, LLP effective on June 3, 2025.

View on SEC.gov

Browse all auditor changes →

Aptevo Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0000950170-25-088970

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.